



ORIGINAL ARTICLE

A Large-Scale, Stratified Genetic Analysis of the Major Histocompatibility Complex Region in Early- and Late-Onset Psoriasis in China

Yi Zhou^{1,2,*}, Minglong Cai^{1,2,*}, Yujun Sheng^{1,2}, Xuejun Zhang^{1,2}¹Department of Dermatology and Institute of Dermatology, First Affiliated Hospital, Anhui Medical University, ²Key Laboratory of Dermatology, Anhui Medical University, Ministry of Education, Hefei, China

Background: Psoriasis vulgaris is a chronic inflammatory skin disease which occur at any age. It can be clinically classified into two age-onset subtypes: early-onset psoriasis (EOP; < 40 years) and late-onset psoriasis (LOP; ≥ 40 years). More evidence showed EOP and LOP have different genetic architecture, notably the risk allele human leukocyte antigen (HLA)-C*06:02 located within the major histocompatibility complex (MHC) region, which was reported to be the outstanding variant associated with EOP. However, genetic structure of EOP and LOP have not been fully elucidated.

Objective: To investigate HLA genetic heterogeneity between EOP and LOP in China. **Methods:** We first calculated the MHC-based heritability of EOP and LOP respectively. Then, we conducted a large-scale, stratified analysis including 7,097 EOP, 1,337 LOP patients, and 9,906 healthy controls by using MHC target sequencing data from a previous

study. **Results:** We observed that HLA alleles collectively explained a larger heritability of EOP (27.4%) than LOP (11.3%). Further association analysis identified three independent loci (HLA-C*01:02, $p = 6.70 \times 10^{-8}$; HLA-A amino acid position 9, $p = 3.27 \times 10^{-17}$; and HLA-A amino acid position 161, $p = 5.75 \times 10^{-10}$) that confer specific susceptibility to EOP. Our data also confirmed HLA-C*06:02 as an independent psoriasis-associated variant, contributing a higher degree of risk to EOP than LOP. Moreover, case-case analysis confirmed that HLA-C*06:02-positive psoriasis patients have earlier onset. **Conclusion:** Our analysis indicating that different genetic background underlie the EOP and LOP. We believe these findings will serve to predict psoriasis risk in the future and facilitate clinical decision. (*Ann Dermatol* 33(1) 61 ~ 67, 2021)

-Keywords-

Genetic heterogeneity, Genetic susceptibility, Genotype-phenotype association, Major histocompatibility complex, Psoriasis

Received April 8, 2020, Revised August 11, 2020, Accepted for publication August 18, 2020

*These authors have equally contributed to the article.

Corresponding author: Yujun Sheng, Department of Dermatology and Institute of Dermatology, First Affiliated Hospital, Anhui Medical University, 69 Meishan Road, Hefei 230032, Anhui, China. Tel: 86-551-65138576, Fax: 86-551-65138576, E-mail: ahmusyj@163.com
ORCID: <https://orcid.org/0000-0002-6022-3359>

Xuejun Zhang, Department of Dermatology and Institute of Dermatology, First Affiliated Hospital, Anhui Medical University, 69 Meishan Road, Hefei 230032, Anhui, China. Tel: 86-551-65138576, Fax: 86-551-65138576, E-mail: ayzjx@vip.sina.com
ORCID: <https://orcid.org/0000-0001-6881-9504>

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © The Korean Dermatological Association and The Korean Society for Investigative Dermatology

INTRODUCTION

Psoriasis vulgaris is a chronic inflammatory skin disease characterized by erythematous, squamous, and thickened plaques. It is a worldwide disease, with prevalence ranging from 0.09% to 11.8%. It affects most races and can manifest at any age of life. Age-onset analyses in psoriasis patients have shown that heredity and clinical course are associated with the age at which the first symptoms of psoriasis are shown. Therefore, psoriasis can be divided into the clinical subtypes, early-onset psoriasis (EOP) and late-onset psoriasis (LOP), with a dividing age of onset of

40 years¹. Compared to LOP, EOP has distinct clinical, evolutionary, and genetic features. EOP comprises the majority of psoriasis patients, is more likely to be familial, and has a severe clinical course¹. For instance, an epidemiologic study of psoriasis reported that EOP patients account for 86.19% of all patients with psoriasis in Han Chinese and EOP patients were more likely to have affected first-degree relatives². On the other hand, LOP patients have a higher likelihood of having psoriasis comorbidities, such as type 2 diabetes and autoimmune thyroiditis. LOP patients are also more likely to be anxious compared with EOP patients³.

The major histocompatibility complex (MHC) region, also known as human leukocyte antigen (HLA) was first associated with psoriasis in 1972⁴. HLA-C*06:02 in the class I HLA region has been proven to be the most significant risk allele for psoriasis in both European⁵ and Chinese populations⁶⁻⁸. In a previous study, our group sequenced the entire 5-Mb MHC region in 10,689 healthy controls and 9,946 psoriasis patients of Han Chinese ancestry. We constructed a Han-MHC database and identified eight independent susceptibility loci associated with psoriasis, including HLA-C*06:02, amino acids at positions 9 and 67 in HLA-B, HLA-C*07:04, rs118179173, amino acid at position 116 in HLA-B, DPB1*05:01, and amino acid at position 281 in BTNL2⁹. Moreover, by analyzing genetic associations between psoriasis subphenotypes divided by age of onset and shared control subjects, our group found that the number of susceptible variants decreased as the onset age of psoriasis increased¹⁰. In addition, several other genetic studies have reported that HLA-C*06 is more strongly associated with EOP in various races¹¹.

Considerable evidence therefore indicates that genetics could play an important role in age of psoriasis onset. However, previous work has been marred by inconsistent results due to low sample sizes, technical variability, and racial stratification. Therefore, we performed a comprehensive, stratified analysis using direct, targeted sequencing data of the MHC to evaluate genetic susceptibility of EOP and LOP patients in a large Han Chinese population.

MATERIALS AND METHODS

Samples

After verification of clinical data, a total of 8,434 patients suffering from psoriasis were enrolled in the study and divided into two groups according to age of onset, including 7,097 EOP (age of onset defined as under 40 years) and 1,337 LOP cases (age of onset defined as 40 years or older), patients with psoriatic arthritis were not included. We also included 9,906 healthy Han Chinese subjects as

controls. All participants provided written informed consent and were recruited according to protocols approved by the institutional ethics committee (No.20131349).

Genotyping and quality control

The HLA sequences were generated, and stringent quality control was conducted, in our previous MHC-targeted sequencing study⁹. In addition, we excluded variants with minor allele frequency (MAF) < 1%, Hardy-Weinberg equilibrium with $p < 10^{-4}$, or a call rate < 99%. Finally, we obtained a total of 26,775 markers including single-nucleotide polymorphisms (SNPs), classic alleles, and amino acid residues. We analyzed SNPs, HLA classic alleles, and HLA amino acid across the MHC region for association with subtypes of psoriasis using a p -value threshold of 1.87×10^{-6} (Bonferroni correction, $0.05/26,775 = 1.87 \times 10^{-6}$) as the cutoff for statistical significance.

Heritability of psoriasis conferred by the MHC locus

After quality control, All SNPs in the MHC region (MAF \geq 1%, Hardy-Weinberg equilibrium with $p > 10^{-4}$, and a call rate $> 99\%$) were included for calculating MHC-based heritability. This was performed by using a variance component model with a genetic relationship matrix implemented in genome-wide complex trait analysis (GCTA)¹². The disease prevalence was set to 0.47% as previously reported¹³.

Statistical analyses

We used a logistic regression model applied in PLINK v.1.9 (Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA)¹⁴ to analyze the associations of all variants with psoriasis susceptibility in each subgroup. The following were analyzed: 1) associations between HLA alleles and EOP susceptibility; 2) associations between HLA alleles and LOP susceptibility; 3) a direct comparison of EOP with LOP. To control for population stratification, we included sex and region as covariates. For stepwise analysis, we included the identified markers as covariates in the logistic regression analysis to condition on them and to further find additional independent variants. This was repeated in a forward stepwise approach until no variation exceeded the predefined significance threshold after Bonferroni correction ($p < 1.87 \times 10^{-6}$). Pearson correlation between variants was calculated by using R version 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria) and the square of correlation coefficient (r^2) was used to measure the correlation level.

Three-dimensional ribbon models for HLA-A

To determine if HLA-A amino acid positions that associated with EOP were located in the binding groove of the

HLA molecule, we used VMD v. 1.92 (Visual Molecular Dynamics; University of Illinois at Urbana-Champaign, Urbana, IL, USA)¹⁵ to prepare HLA-A structures based on Protein Data Bank entry 1×7q¹⁶.

Statistical power calculation

Statistical power of our study was evaluated by Power and Sample Size Software v.3.1.2 (Vanderbilt University School of Medicine, Nashville, TN, USA). The type I error was set to 1.87×10^{-6} .

RESULTS

HLA contributes a greater proportion of the heritability of EOP than LOP

Using GCTA, we calculated that HLA alleles collectively explained more phenotypic variance of EOP (27.4%, standard error [SE]=0.010) than LOP (11.3%, SE=0.015), implying that EOP has a much stronger genetic component than LOP. To further investigate this result, we performed a comprehensive, stratified analysis to search for psoriasis age-of-onset-specific risk alleles.

EOP versus control

The results of our association analysis of the MHC region

with EOP susceptibility are shown in Table 1. As previously reported^{1,17}, the strongest association observed was between the HLA-C*06:02 allele and EOP ($p=1.00 \times 10^{-1,027}$), followed by HLA-C*07:04 ($p=2.43 \times 10^{-38}$). In addition, the allele HLA-C*01:02 also showed a significant association ($p=6.70 \times 10^{-8}$), which has not been reported previously. After conditioning on HLA-C, rs118179173 ($p=9.20 \times 10^{-67}$) was the top signal. Further conditional analysis identified two new amino acids in the HLA-A gene (position 9, $p=3.27 \times 10^{-17}$; and position 161, $p=5.75 \times 10^{-10}$). When we conditioned on HLA-C, rs118179173, and HLA-A, a significant independently associated signal for HLA-DPB1*05:01 ($p=2.00 \times 10^{-15}$) was observed. We also showed independent associations at three amino acids in the HLA-B gene (position 9, $p=1.10 \times 10^{-14}$; position 67, $p=8.26 \times 10^{-17}$, and position 116; $p=1.20 \times 10^{-6}$), which were reported to be associated with psoriasis as a whole in our previous study. In addition, we verified an association signal on BTNL2:M295V ($p=2.57 \times 10^{-7}$), which was strongly correlated with a previously reported variant for BTNL2:R281K ($r^2=0.953$, $p<2.2 \times 10^{-16}$) in our dataset⁹. When conditioning on all the above loci, no association reached the predefined significance threshold (Supplementary Fig. 1).

Table 1. Association of HLA variants with EOP and LOP in China

| HLA variant | EOP vs. Control | | | | LOP vs. Control | | | | EOP vs. LOP | | | |
|------------------|-----------------|------------------|-------------------|--------------------------|-----------------|------------------|-------------------|-------------------------|--------------|--------------|-------------------|------------------------|
| | Frequency | | OR (95% CI) | <i>p</i> -value* | Frequency | | OR (95% CI) | <i>p</i> -value* | Frequency | | OR (95% CI) | <i>p</i> -value* |
| | Freq_ EOP | Freq_ Control | | | Freq_ LOP | Freq_ Control | | | Freq_ EOP | Freq_ LOP | | |
| HLA-C alleles | | | | | | | | | | | | |
| C*06:02 | 0.4522 | 0.1104 | 16.48 | 1.00×10^{-1072} | 0.3624 | 0.1104 | 5.982 | 2.37×10^{-222} | 0.4522 | 0.3624 | 2.101 | 1.71×10^{-32} |
| C*07:04 | 0.01529 | 0.0102 | 4.418 | 2.43×10^{-38} | 0.01907 | 0.0102 | 3.483 | 1.81×10^{-13} | - | - | - | - |
| C*01:02 | 0.1031 | 0.1387 | 1.271 | 6.70×10^{-8} | - | - | - | - | - | - | - | - |
| rs118179173 | 0.04516 | 0.0317 | 3.994 | 9.20×10^{-67} | - | - | - | - | - | - | - | - |
| HLA-A alleles | | | | | | | | | | | | |
| A-F9 | 0.371 | 0.3288 | 1.289 | 3.27×10^{-17} | - | - | - | - | - | - | - | - |
| A-D161E | 0.026 | 0.03765 | 0.5781 | 5.75×10^{-10} | - | - | - | - | - | - | - | - |
| HLA-DPB1 alleles | | | | | | | | | | | | |
| DPB1*05:01 | 0.3597 | 0.3643 | 1.277 | 2.00×10^{-15} | - | - | - | - | - | - | - | - |
| HLA-B alleles | | | | | | | | | | | | |
| B-Y9 | 0.1668 | 0.2165 | 0.7458 | 1.10×10^{-14} | - | - | - | - | - | - | - | - |
| B-A41T | - | - | - | - | 0.3728 | 0.3231 | 0.6912 | 6.71×10^{-12} | - | - | - | - |
| B-Y67C | 0.09053 | 0.08742 | 1.733 | 8.26×10^{-17} | 0.1043 | 0.08742 | 1.568 | 1.81×10^{-8} | - | - | - | - |
| B-Y116S | 0.3137 | 0.3262 | 1.188 | 1.20×10^{-6} | - | - | - | - | - | - | - | - |
| BTNL2 alleles | | | | | | | | | | | | |
| BTNL2: M295V | 0.05693 | 0.06405 | 1.373 | 2.57×10^{-07} | - | - | - | - | - | - | - | - |

HLA: human leukocyte antigen, EOP: early-onset psoriasis, LOP: late-onset psoriasis, OR: odds ratio, CI: confidence interval, -: not available. **p*-value from stepwise regression analysis.

LOP versus control

The results of association analysis of the MHC region with LOP susceptibility are shown in Table 1. We identified HLA-C*06:02 ($p=2.37 \times 10^{-222}$) and HLA-C*07:04 ($p=1.81 \times 10^{-13}$) associated with LOP. When we conditioned on HLA-C*06:02 and HLA-C*07:04, we observed that HLA-B amino acid position 41 ($p=6.71 \times 10^{-12}$) and amino acid position 67 ($p=1.81 \times 10^{-8}$) remained independently associated with LOP (Supplementary Fig. 2).

EOP versus LOP

In order to further reveal the HLA genetic heterogeneity between psoriasis subtypes, we carried out case-only analysis by making direct comparisons between the EOP and LOP groups. HLA-C*06:02 ($p=1.71 \times 10^{-32}$) reached our predefined significance threshold (Table 1). After we conditioned on HLA-C*06:02, no new loci or genes were observed (Fig. 1).

DISCUSSION

In this study, we first calculated the MHC-derived heritability of EOP and LOP individually, observing that HLA alleles collectively explained a larger proportion of the phenotypic variance of EOP (27.4%) than LOP (11.3%). Next, we fine-mapped HLA associations in EOP and LOP.

As previously reported, HLA-C*06:02 was the most significant association with EOP^{1,17}, and HLA-C*06:02-positive psoriasis patients had earlier onset¹¹. We also detected a significant association between HLA-C*06:02 and LOP. HLA-C*06:02, HLA-C*07:04, and amino acid position 67 in HLA-B have been confirmed both in EOP-control and LOP-control studies in the Han Chinese population. This suggests that these three loci are strongly associated with psoriasis in the Han Chinese population, while other loci showed onset-specific associations with psoriasis. Further study of LOP vs. EOP confirmed HLA-C*06:02 as a risk factor in psoriasis, contributing more risk to EOP ($p=1.71 \times 10^{-32}$). Therefore, we have conducted a systematic, stratified analysis of psoriasis associations in the MHC, and defined genetic heterogeneity between EOP and LOP subtypes.

In our MHC-region association analysis comparing EOP patients and controls, we found eleven independent susceptibility loci (Table 1). Seven of them (HLA-C*06:02, HLA-C*07:04, rs118179173, HLA-DPB1*05:01, and amino acids at positions 9, 67, and 116 in HLA-B) have previously reported associations with psoriasis in the Han Chinese population. One (BTNL2:M295V) is in strong linkage disequilibrium with BTNL2:R281K ($r^2=0.953$, $p<2.2 \times 10^{-16}$), which has also been reported to be associated with psoriasis⁹. Hence, we have confirmed all eight psoriasis-risk HLA loci from our previous psoriasis-control ana-




Fig. 1. Stepwise Conditional Association Analysis between early-onset psoriasis (EOP) and late-onset psoriasis (LOP). Association analysis of human leukocyte antigen (HLA)-C in EOP versus LOP. The horizontal axis shows genomic position and the vertical axis shows negative log₁₀-transformed *p*-values of associations. The dashed horizontal line corresponds to the significance threshold of $p=1.87 \times 10^{-6}$. The red triangles represent the most associated variants. The yellow triangles represent amino acid positions. The green triangles represent HLA alleles and the grey triangles represent single-nucleotide polymorphisms (SNPs).

lysis. Moreover, we identified three novel loci (HLA-C*01:02, and amino acids 9, and 161 in HLA-A) associated with EOP, but not with psoriasis. Notably, HLA-C*01:02 has been reported to be associated with psoriasis in the southern Chinese population¹⁸. HLA-A amino acids 9 and 161 are located at functional pockets of HLA-A molecules, suggesting potential biological significance (Fig. 2). These findings suggest that HLA-C*01:02, and amino acids 9 and 161 of HLA-A may serve as EOP-specific susceptibility loci.

Previous small case-control studies have not found associations between HLA-C alleles and LOP^{19,21}. However, we observed four independent loci (HLA-C*06:02, HLA-C*07:04, and HLA-B amino acids 41 and 67) (Table 1) associated with LOP. In contrast to previous studies^{19,20}, HLA-C*06:02 had the strongest association with LOP in our data. Also of note, HLA-B amino acid 41 was independently associated with LOP, and not with EOP, while HLA-B amino acids 9 and 116 were independently associated with EOP, and not with LOP. In order to confirm whether HLA-B amino acid 41 is an LOP-specific risk loci, we conducted a linkage analysis of three amino acid loci in HLA-B (amino acids 9, 41, and 116). We found that HLA-B amino acid 9 is in weak linkage with HLA-B amino acid 41 ($r^2=0.113$, $p<2.2\times 10^{-16}$) and HLA-B amino acid 116 ($r^2=0.096$, $p<2.2\times 10^{-16}$). In EOP-control analysis, when we conditioned on HLA-B amino acids 41 and 116/9, 116/9 still reached our significance threshold ($p=1.47\times 10^{-11}$ and $p=1.18\times 10^{-6}$ respectively). However, when




Fig. 2. Three-dimensional ribbon models for human leukocyte antigen (HLA)-A. The protein structures of HLA-A are based on Protein Data Bank entries 1x7q and prepared using VMD (version 1.92). The green spheres represent amino acid residues at HLA amino acid position 9 and 161 respectively. Number 9 represent HLA amino acid position 9. Number 161 represent HLA amino acid position 161.

conditioned on amino acids 116 and 9 in our LOP-control cohort, HLA-B amino acid 41 did not meet the significance threshold in LOP-control analysis ($p=0.0012$). This means that the LOP-associated variant HLA-B amino acid 41 was not independent of EOP-associated HLA-B variants. Further, HLA-B amino acid position 41 was not located at antigenic peptide binding pockets in three-dimensional ribbon models. We therefore speculate that HLA-B amino acid 41 is not an independent LOP-specific susceptibility locus.

We further directly compared EOP with LOP and confirmed that HLA-C*06:02 contributes more risk to EOP. Comparing the results from EOP-control and LOP-control studies, we have identified eight susceptibility loci (HLA-C*01:02, rs118179173, HLA-DPB1*05:01, HLA-A amino acids 9 and 161, HLA-B amino acids 9 and 116, and BTNL2) associated with EOP. However, we didn't verify these loci in EOP vs. LOP analysis. It is possible that this is due to our smaller LOP sample size, which could influence the detection of susceptibility loci in LOP vs. control and EOP vs. LOP. We calculated the power of LOP-control analysis for detecting HLA-C*01:02, rs118179173, HLA-A amino acids 9, and 161, HLA-B amino acids 9 and 116, DPB1*05:01, and BTNL2:M295V were 5.5%, 100%, 30.2%, 1.1%, 16.0%, 2.9%, 26.9%, and 5.6%, respectively, most of which were below 80%. There is a possibility that some of the EOP-associated variants were also conferring risk for LOP, but we did not have sufficient power to detect them. Also, the smaller sample size of our EOP-LOP analysis suggests that the case-case analysis had lower power, which may have caused EOP-specific variants to go undetected. However, it is noteworthy that our previous psoriasis-control study had a larger sample size than the EOP-control analysis in this study, while the results of our EOP association analysis validated all previously identified psoriasis-risk variants. Further, of the three novel EOP susceptibility HLA loci: HLA-C*01:02, and HLA-A amino acids 9 and 161, the first one was reported to be associated with schizophrenia in Europeans²² and the latter two variants (HLA-A amino acids 9 and 161) were reside in peptide-binding grooves of HLA (Fig. 2). Hence, we have good reason to believe that the three novel independent loci are susceptibility factors specific to EOP, at least in the Han Chinese population. However, the functional mechanisms of these variants in EOP are unknown. It is possible that they constitute or contain specific peptide-binding grooves in HLA-A/HLA-C molecules²³, presenting restricted auto-antigens and further modulating adaptive immune responses. For example, an unbiased analysis indicated that CD8⁺ T recognizes an HLA*06:02-restricted melanocytic ADAMTSL5 in psoriasis²⁴. Further studies on the mechanisms under-

lying searches for allele-restricted auto-antigens are needed. We also compared our new results with those from previously published psoriasis association analyses of the MHC region in other populations. One study identified an association between HLA-C*12:02 and LOP in a Japanese cohort²¹. However, in a Brazilian study²⁵ and a UK Caucasian population¹⁷, no association was detected between HLA-C*12:02 and LOP. In our dataset, HLA-C*12:02 did not meet the significance threshold.

In conclusion, we have conducted a comprehensive, stratified analysis of genetic variation in the MHC region in relation to psoriasis. We found that EOP has a stronger genetic background than LOP and we identified three novel independent loci (HLA-C*01:02, and HLA-A amino acids 9 and 161) that showed onset-specific association with EOP in the Han Chinese population. Moreover, case-case analysis confirmed that HLA-C*06:02-positive psoriasis patients have earlier onset. We believe these findings will serve to predict psoriasis risk in the future and facilitate clinical decision.

ACKNOWLEDGMENT

We are grateful to all participants, their families and healthy controls who donated blood samples in this study.

SUPPLEMENTARY MATERIALS

Supplementary data can be found via <http://anndermatol.org/src/sm/ad-33-061-s001.pdf>.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

FUNDING SOURCE

This work was supported by the National Natural Science Foundation of China (81872527, 81803117) and the study sponsors took part in study design, review and decision to submit the manuscript for publication.

DATA SHARING STATEMENT

The raw sequencing data from samples evaluated in the Han-MHC project have been deposited in the Sequence Read Archive (SRA) under the accession SRA205317.

ORCID

Yi Zhou, <https://orcid.org/0000-0002-7887-6120>

Minglong Cai, <https://orcid.org/0000-0002-5038-3703>

Yujun Sheng, <https://orcid.org/0000-0002-6022-3359>

Xuejun Zhang, <https://orcid.org/0000-0001-6881-9504>

REFERENCES

1. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. *J Am Acad Dermatol* 1985;13:450-456.
2. Zhang X, Wang H, Te-Shao H, Yang S, Chen S. The genetic epidemiology of psoriasis vulgaris in Chinese Han. *Int J Dermatol* 2002;41:663-669.
3. Theodorakopoulou E, Yiu ZZ, Bundy C, Chularojanamontri L, Gittins M, Jamieson LA, et al. Early- and late-onset psoriasis: a cross-sectional clinical and immunocytochemical investigation. *Br J Dermatol* 2016;175:1038-1044.
4. Russell TJ, Schultes LM, Kuban DJ. Histocompatibility (HL-A) antigens associated with psoriasis. *N Engl J Med* 1972;287:738-740.
5. Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NVC, Jenisch S, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. *Am J Hum Genet* 2006;78:827-851.
6. Zhang XJ, He PP, Wang ZX, Zhang J, Li YB, Wang HY, et al. Evidence for a major psoriasis susceptibility locus at 6p21 (PSORS1) and a novel candidate region at 4q31 by genome-wide scan in Chinese hans. *J Invest Dermatol* 2002;119:1361-1366.
7. Fan X, Yang S, Huang W, Wang ZM, Sun LD, Liang YH, et al. Fine mapping of the psoriasis susceptibility locus PSORS1 supports HLA-C as the susceptibility gene in the Han Chinese population. *PLoS Genet* 2008;4:e1000038.
8. Zhang XJ, Huang W, Yang S, Sun LD, Zhang FY, Zhu QX, et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. *Nat Genet* 2009;41:205-210.
9. Zhou F, Cao H, Zuo X, Zhang T, Zhang X, Liu X, et al. Deep sequencing of the MHC region in the Chinese population contributes to studies of complex disease. *Nat Genet* 2016;48:740-746.
10. Ye L, Yang C, Dou JF, Wen LL, Wang WJ, Zheng XD, et al. Genetic factors are stressed variably by onset age-based sample selection in psoriasis: a hint from major histocompatibility complex region-based analysis. *J Gene Med* 2017;19:e2997.
11. Gudjonsson JE, Karason A, Runarsdottir EH, Antonsdottir AA, Hauksson VB, Jónsson HH, et al. Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients—an analysis of 1019 HLA-C- and HLA-B-typed patients. *J Invest Dermatol* 2006;126:740-745.
12. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. *Am J Hum Genet* 2011;88:76-82.
13. Ding X, Wang T, Shen Y, Wang X, Zhou C, Tian S, et al. Prevalence of psoriasis in China: a population-based study in six cities. *Eur J Dermatol* 2012;22:663-667.
14. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM,

- Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* 2015;4:7.
15. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. *J Mol Graph* 1996;14:33-38, 27-28.
 16. Blicher T, Kastrup JS, Buus S, Gajhede M. High-resolution structure of HLA-A*1101 in complex with SARS nucleocapsid peptide. *Acta Crystallogr D Biol Crystallogr* 2005;61(Pt 8): 1031-1040.
 17. Mallon E, Bunce M, Wojnarowska F, Welsh K. HLA-CW*0602 is a susceptibility factor in type I psoriasis, and evidence Ala-73 is increased in male type I psoriatics. *J Invest Dermatol* 1997;109:183-186.
 18. Cai M, Huang H, Ran D, Zheng X, Wen L, Zhu Z, et al. HLA-C*01:02 and HLA-A*02:07 confer risk specific for psoriatic patients in Southern China. *J Invest Dermatol* 2019; 139:2045-2048.e4.
 19. Allen MH, Ameen H, Veal C, Evans J, Ramrakha-Jones VS, Marsland AM, et al. The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis. *J Invest Dermatol* 2005;124:103-106.
 20. Szczerkowska-Dobosz A, Niespodziana K, Rebała K, Garstecka J, Lange M, Barańska-Rybak W. Lack of association of HLA-C alleles with late-onset psoriasis in the northern Polish population. *J Appl Genet* 2007;48:273-275.
 21. Mabuchi T, Ota T, Manabe Y, Ikoma N, Ozawa A, Terui T, et al. HLA-C*12:02 is a susceptibility factor in late-onset type of psoriasis in Japanese. *J Dermatol* 2014;41:697-704.
 22. Irish Schizophrenia Genomics Consortium and the Wellcome Trust Case Control Consortium 2. Genome-wide association study implicates HLA-C*01:02 as a risk factor at the major histocompatibility complex locus in schizophrenia. *Biol Psychiatry* 2012;72:620-628.
 23. Prinz JC. Human leukocyte antigen-class I alleles and the autoreactive T cell response in psoriasis pathogenesis. *Front Immunol* 2018;9:954.
 24. Arakawa A, Siewert K, Stöhr J, Besgen P, Kim SM, Rühl G, et al. Melanocyte antigen triggers autoimmunity in human psoriasis. *J Exp Med* 2015;212:2203-2212.
 25. Biral AC, Magalhaes RF, Wastowski IJ, Simoes R, Donadi EA, Simoes AL, et al. Association of HLA-A, -B, -C genes and TNF microsatellite polymorphism with psoriasis vulgaris: a study of genetic risk in Brazilian patients. *Eur J Dermatol* 2006;16:523-529.